Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biostar Pharmaceuticals (BSPM), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, has announced that it has filed PRC national invention and creation patent for the pharmaceutical and preparation method of its new developed product, Oleanolic Acid Injection, which designed to treat Hepatitis B and liver cancer.
Subscribe to our email newsletter
The application passed the preliminary examination of the PRC State Intellectual Property Bureau and was accepted for review; the application acceptance number is 201410182757.7.
The filed patent is for the pharmaceutical and preparation method developed by the Company’s R&D team, together with the experts of Shaanxi University of Chinese Medicine after nearly 2 years of research and development effort.
It is one of drug development efforts by the Company in combating Hepatitis B and liver cancer and is currently under pharmacological research.
Mr. Ronghua Wang, Chairman of the Company commented: "The filing and acceptance for review of the invention patent application indicates that the Company had made considerable progress in developing its Oleanolic Acid Injection. This promises to establish technical foundation for the product’s research and development and future expansion. The Company will continue to increase investment in its research and development efforts to generate effective drugs for the PRC markets."